Trelegy Ellipta Prescribing & Dosing Schedule

Dosage & Administration Drug label Samples Prior authorization Financial assistance Patient education People also ask

Trelegy Ellipta (fluticasone furoate)

TRELEGY ELLIPTA 100 MCG / 62.5 MCG / 25 MCG Dry Powder Inhaler, 14 Blisters

NO BOXED WARNING

Dosage & Administration

* For oral inhalation only.
* Maintenance treatment of COPD: 1 actuation of TRELEGY ELLIPTA 100/62.5/25 mcg once daily administered by oral inhalation.
* Maintenance treatment of asthma: 1 actuation of TRELEGY ELLIPTA 100/62.5/25 mcg or TRELEGY ELLIPTA 200/62.5/25 mcg once daily administered by oral inhalation.

drug label

Trelegy Ellipta Prescribing Information

Contact Medical Science Liaison

Report Adverse Event

samples

Request Trelegy Ellipta Samples

Online Sample Form

Learn More

prior authorization

Trelegy Ellipta Prior Authorization Resources

Most recent state uniform prior authorization forms

Verified: Jun 26, 2024Arizona - Uniform Prior Authorization Form

Verified: Jun 26, 2024Colorado - Uniform Prior Authorization Form

Verified: Jun 26, 2024Hawaii - Uniform Prior Authorization Form

Verified: Jul 26, 2024Illinois - Uniform Prior Authorization Form

Verified: Jun 26, 2024Indiana - Uniform Prior Authorization Form

Verified: Jun 26, 2024Louisiana - Uniform Prior Authorization Form

Verified: Jun 26, 2024Minnesota - Uniform Prior Authorization Form

Verified: Jun 26, 2024New Hampshire - Uniform Prior Authorization Form

Verified: Jun 26, 2024New Mexico - Uniform Prior Authorization Form

Verified: Jun 26, 2024Oregon - Uniform Prior Authorization Form

Verified: Jun 26, 2024Texas - Uniform Prior Authorization Form

Verified: Jul 07, 2024Washington - Uniform Prior Authorization Form

Verified: Jul 07, 2024Wisconsin - Uniform Prior Authorization Form

Benefits investigation

Patient Authorization Form - GSKForYou

Reimbursement help (FRM)

Receive Assistance from an FRM Regarding Reimbursement Information

financial assistance

Trelegy Ellipta Financial Assistance Options

Copay savings program

Enroll in Patient Savings Program

Learn More

Overview

Reduce patient OOP costs for drug (and occasionally for drug administration/infusion costs or drug-related test costs)

Patient benefit

A portion (or all) of patient OOP (deductible, copay), typically up to monthly and/or annual max

Patient eligibility

Patient must enroll or activate (may permit HCPs to enroll on patient’s behalf for HCP-administered drugs)
Generally, must have commercial insurance (rarely, may permit uninsured patients to use)
May never be used with government insurance

How to sign up

Cards may be downloadable digital cards or hard copies
Some pharmacos offer debit cards with pre-loaded copay benefit
Typically, available through multiple channels (e.g., rep to HCP to patient; pharmacy to patient; patient via website, Hub live agent, or copay vendor (live agent or IVR); patient and HCP via Hub enrollment form)
Some HCP-administered product programs permit HCPs to enroll on a patient’s behalf through via Hub form

Foundation programs

GSK Patient Assistance Program

Learn More

Overview

Charitable 501(c)(3) organizations provide direct cost-sharing and other support (e.g., travel, counseling) through disease-state funds to indigent patients on first-come first-served basis
These organizations may receive financial contributions from drug manaufacturers for particular disease-state funds that cannot provide funds directly to patients - the foundation must be independent/unaligned

Patient benefit

Patients apply for grants that cover a portion (or all) of their out-of-pocket costs (deductibles and copays) until the grant is exhausted

Patient eligibility

Patients must apply and meet eligibility criteria including income level (typically a multiple of federal poverty line), specific diagnosis, insurance status, etc.

How to sign up

Patients submit proof of out-of-pocket drug costs to charities for reimbursement

patient education

Trelegy Ellipta Patient Education

Getting started on Trelegy Ellipta

Instructions For Use: COPD

ASK PATIENT TO:
Open Camera on Phone
Scan QR Code & Tap Link

Instructions For Use: Asthma

ASK PATIENT TO:
Open Camera on Phone
Scan QR Code & Tap Link

Instructions For Use (Spanish): COPD & Asthma

ASK PATIENT TO:
Open Camera on Phone
Scan QR Code & Tap Link

To share resource; ask patient to:

1.Pull out phone

2.Open camera

3.Scan QR code with camera

4.Tap link

Patient toolkit

About Trelegy Ellipta: COPD

ASK PATIENT TO:
Open Camera on Phone
Scan QR Code & Tap Link

Doctor Discussion Guide: COPD

ASK PATIENT TO:
Open Camera on Phone
Scan QR Code & Tap Link

Patient Stories: COPD

ASK PATIENT TO:
Open Camera on Phone
Scan QR Code & Tap Link

About Trelegy Ellipta: Asthma

ASK PATIENT TO:
Open Camera on Phone
Scan QR Code & Tap Link

Patient Stories: Asthma

ASK PATIENT TO:
Open Camera on Phone
Scan QR Code & Tap Link

Using Trelegy Ellipta

ASK PATIENT TO:
Open Camera on Phone
Scan QR Code & Tap Link

Patient Resources: COPD

ASK PATIENT TO:
Open Camera on Phone
Scan QR Code & Tap Link

Patient Resources: Asthma

ASK PATIENT TO:
Open Camera on Phone
Scan QR Code & Tap Link

Doctor Discussion Guide: Asthma

ASK PATIENT TO:
Open Camera on Phone
Scan QR Code & Tap Link

Asthma Action Plan

ASK PATIENT TO:
Open Camera on Phone
Scan QR Code & Tap Link

Asthma Control Test

ASK PATIENT TO:
Open Camera on Phone
Scan QR Code & Tap Link

Asthma Control Test: Spanish

ASK PATIENT TO:
Open Camera on Phone
Scan QR Code & Tap Link

COPD Assesment Test

ASK PATIENT TO:
Open Camera on Phone
Scan QR Code & Tap Link

Trelegy Ellipta FAQs

8.1 Pregnancy Risk SummaryInsufficient data are available on the use of TRELEGY ELLIPTA or its individual components (fluticasone furoate, umeclidinium, and vilanterol) in pregnant women to determine a drug-associated risk. Animal studies showed no adverse effects on embryofetal development for these components at exposures approximately 4.5 to 200 times the maximum recommended daily inhalation doses in adults.

8.2 Lactation Risk SummaryNo information is available on the presence of these components in human milk, their effects on the breastfed child, or milk production. Umeclidinium was detected in the plasma of offspring of lactating rats treated with umeclidinium, suggesting its presence in maternal milk.

8.4 Pediatric UseTRELEGY ELLIPTA is not approved for use in pediatric patients, and its safety and efficacy in pediatric patients have not been established.

8.5 Geriatric UseNo dosage adjustment is necessary for geriatric patients, but greater sensitivity in some older individuals cannot be ruled out.

8.6 Hepatic ImpairmentTRELEGY ELLIPTA has not been studied in subjects with hepatic impairment. Information on the individual components is provided.

8.7 Renal ImpairmentTRELEGY ELLIPTA has not been studied in subjects with renal impairment. Information on the individual components is provided.

FAQ Data Source

Dosage & Administration

Dosage & Administration

drug label

Trelegy Ellipta Prescribing Information

samples

Request Trelegy Ellipta Samples

Is my patient eligible for Trelegy Ellipta samples?

How do I find out who my Trelegy Ellipta rep is?

prior authorization

Trelegy Ellipta Prior Authorization Resources

Most recent state uniform prior authorization forms

Benefits investigation

Reimbursement help (FRM)

financial assistance

Trelegy Ellipta Financial Assistance Options

Copay savings program

Overview

Patient benefit

Patient eligibility

How to sign up

Foundation programs

Overview

Patient benefit

Patient eligibility

How to sign up

patient education

Trelegy Ellipta Patient Education

Getting started on Trelegy Ellipta

Patient toolkit

people also ask

Trelegy Ellipta FAQs